Granules India gets licence from DRDO to manufacture and market COVID-19 drug 2-DG

Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, Granules India said in a filing to BSE.